Hormonal Birth Control May Slightly Increase the Risk of Brain Tumors, European Medicines Agency Warns
Meta Description
The European Medicines Agency (EMA) has warned that long-term use of certain hormonal contraceptives containing desogestrel and etonogestrel may slightly increase the risk of developing meningioma, a usually non-cancerous brain tumor. Learn about the findings, symptoms, risk factors, and expert recommendations.
 |
| Hormonal Birth Control May Slightly Increase the Risk of Brain Tumors, European Medicines Agency Warns |
Hormonal Birth Control May Slightly Increase Brain Tumor Risk: What Women Need to Know
Millions of women worldwide rely on hormonal birth control for pregnancy prevention, menstrual regulation, and treatment of hormonal disorders. While these medications are generally considered safe and effective, the European Medicines Agency (EMA) has issued a new safety recommendation after reviewing evidence suggesting that prolonged use of contraceptives containing desogestrel or etonogestrel may be linked to a slight increase in the risk of developing meningioma, a type of brain tumor.
The agency emphasized that the overall risk remains very low, but healthcare providers and patients should be aware of the potential association, especially during long-term treatment.
Key Takeaways
The EMA reviewed evidence linking certain hormonal contraceptives to meningioma.
Long-term use of desogestrel and etonogestrel may slightly increase the risk.
The overall likelihood remains extremely low.
Women with a current or previous meningioma should avoid these contraceptives.
Healthcare providers should monitor users for neurological symptoms.
Product information will now include meningioma as a possible side effect.
Experts stress that women should not stop contraception without consulting their doctor.
"The overall benefits of hormonal contraception continue to outweigh the risks for most women, but informed decision-making is essential."
What Did the European Medicines Agency Announce?
The European Medicines Agency (EMA) announced that its Pharmacovigilance Risk Assessment Committee (PRAC) reviewed data indicating a possible association between prolonged exposure to specific synthetic progestins and the development of meningioma.
The committee concluded that contraceptives containing:
Desogestrel
Etonogestrel
may slightly increase the risk of this type of tumor after extended use.
Although the increase is statistically measurable, experts stressed that the absolute risk remains extremely small.
What Is a Meningioma?
A meningioma is the most common type of tumor that develops in the membranes surrounding the brain and spinal cord, known as the meninges.
In most cases, these tumors are:
Benign (non-cancerous)
Slow-growing
Treatable
Diagnosed later in life
However, depending on their size and location, they can press against nearby brain structures and cause neurological symptoms.
Why Are Hormonal Contraceptives Being Investigated?
Researchers have long suspected that certain hormones may influence the growth of meningiomas because many of these tumors contain progesterone receptors.
Synthetic hormones known as progestins are widely used in:
Birth control pills
Hormonal implants
Vaginal rings
Hormone replacement therapy
Treatments for gynecological conditions
Previous studies had already linked several progestins—including cyproterone acetate, nomegestrol, medroxyprogesterone acetate, and chlormadinone—to a higher risk of meningioma.
The latest EMA review extends this concern to desogestrel and etonogestrel, although the observed risk appears considerably lower.
Which Birth Control Methods Are Included?
According to the EMA, the safety warning concerns hormonal contraceptives containing:
Desogestrel
Usually available as:
Oral contraceptive pills
Progestin-only pills ("mini-pills")
Etonogestrel
Available as:
Contraceptive implants
Vaginal contraceptive rings
Women using these products should not panic, as the risk remains very small.
How Much Does the Risk Increase?
One of the most reassuring findings is that the increase in risk is minimal.
According to the European Medicines Agency:
Approximately one additional case of meningioma may occur for every 67,300 women using these contraceptives.
This means that although the association exists, the overwhelming majority of women using these medications will never develop a meningioma.
Why Does Long-Term Use Matter?
The EMA stated that the risk appears to increase with:
Longer duration of use
Higher cumulative exposure
Previous exposure to other high-risk progestins
Women who previously used medications containing:
Cyproterone
Nomegestrol
Medroxyprogesterone
Chlormadinone
may experience a relatively higher risk compared with women who have never taken those medications.
"The overall risk remains extremely low, but longer exposure appears to increase the likelihood of developing meningioma."
Who Should Avoid These Hormonal Contraceptives?
The EMA now recommends that women with:
A current diagnosis of meningioma
A previous history of meningioma
should not use contraceptives containing desogestrel or etonogestrel.
Instead, healthcare professionals should discuss alternative birth control methods tailored to each patient's medical history.
Symptoms That Should Never Be Ignored
Although meningiomas usually grow slowly, they may eventually produce neurological symptoms.
Women should contact their healthcare provider if they experience:
Persistent headaches
Worsening migraines
Blurred or double vision
Hearing loss
Ringing in the ears
Balance problems
Weakness in the arms or legs
Memory difficulties
Personality changes
Seizures
Early medical evaluation allows timely diagnosis and treatment if necessary.
What Should Healthcare Providers Do?
The EMA recommends that physicians:
Review patients' medical histories carefully.
Evaluate previous exposure to other progestin-containing medications.
Monitor long-term users for neurological symptoms.
Inform patients about the signs of meningioma.
Consider alternative contraceptive options when appropriate.
Shared decision-making between physicians and patients remains the cornerstone of safe contraceptive care.
The French Study Behind the EMA Recommendation
The EMA's latest recommendations are based on findings from a large nationwide French study that examined the relationship between hormonal contraceptive use and the development of meningioma.
Researchers analyzed health records from thousands of women over several years, comparing those who had used progestin-based contraceptives with women who had not.
The study found that:
Longer exposure to certain synthetic progestins was associated with a slightly higher incidence of meningioma.
The increased risk varied depending on the type of hormone, dosage, and duration of use.
Women who had previously used other progestins already known to increase the risk appeared to have a somewhat greater likelihood of developing the condition.
Although the study identified an association, researchers emphasized that it does not prove a direct cause-and-effect relationship. Other medical and genetic factors may also contribute to tumor development.
Why Does the Overall Risk Remain Low?
Despite the new warning, experts stress that the likelihood of developing meningioma remains extremely small.
Several reasons explain why women should not panic:
Meningiomas are relatively uncommon.
Most meningiomas are benign rather than cancerous.
Only a very small number of users are affected.
Many tumors are successfully treated when detected early.
The benefits of effective contraception remain significant for millions of women.
The EMA estimates approximately one additional case per 67,300 women, highlighting that the increased risk is statistically detectable but clinically rare.
Benefits of Hormonal Birth Control
While recent headlines have focused on potential risks, it is equally important to recognize the well-established benefits of hormonal contraception.
These medications can help:
Prevent unintended pregnancy.
Regulate menstrual cycles.
Reduce painful menstrual cramps.
Treat heavy menstrual bleeding.
Improve symptoms of endometriosis.
Reduce acne in some women.
Lower the risk of ovarian and endometrial cancers.
Improve quality of life for women with hormonal disorders.
For most healthy women, these benefits continue to outweigh the small potential risks.
Hormonal vs. Non-Hormonal Birth Control
| Feature | Hormonal Birth Control | Non-Hormonal Birth Control |
|---|---|---|
| Pregnancy prevention | Excellent | Excellent (depending on method) |
| Hormone exposure | Yes | No |
| Menstrual regulation | Yes | Usually No |
| Acne improvement | Sometimes | No |
| Endometriosis treatment | Yes | No |
| Possible meningioma concern | Slight increase with certain progestins | No known association |
| Suitable after meningioma diagnosis | Generally not recommended (certain products) | Often preferred |
Women should discuss these options with their healthcare provider to determine which method best suits their medical history and personal preferences.
Who Is Most Likely to Need Medical Advice?
Women should schedule a medical consultation if they:
Have previously been diagnosed with meningioma.
Have undergone brain tumor surgery.
Experience persistent neurological symptoms.
Have used progestin-containing contraceptives for many years.
Previously received treatment with cyproterone acetate, medroxyprogesterone acetate, nomegestrol, or chlormadinone.
Are considering long-term hormonal contraception.
Should Women Stop Taking Their Birth Control Immediately?
The answer is No.
Medical experts strongly advise women not to discontinue hormonal contraceptives without consulting a healthcare professional.
Stopping birth control suddenly may result in:
Unintended pregnancy.
Hormonal imbalance.
Irregular menstrual cycles.
Return of symptoms being treated with hormonal therapy.
Instead, women should discuss any concerns with their physician, who can determine whether switching to another contraceptive method is appropriate.
Expert Recommendations
Healthcare specialists recommend the following:
Do not panic after reading the EMA announcement.
Continue taking medication unless advised otherwise by your doctor.
Attend regular medical checkups.
Report persistent headaches or neurological symptoms promptly.
Discuss alternative contraceptive methods if you have a history of meningioma.
Carefully review your personal medical history before starting long-term hormonal therapy.
The Importance of Early Detection
Although meningiomas are usually benign, early diagnosis remains essential.
Doctors may recommend imaging tests such as MRI scans when neurological symptoms appear.
Early detection often allows:
Less invasive treatment.
Better long-term outcomes.
Lower risk of permanent neurological complications.
Greater treatment success.
What This Means for Women Worldwide
The EMA's announcement should be viewed as an effort to improve patient safety rather than a reason for alarm.
Medical recommendations continue to evolve as new evidence becomes available. Regulatory agencies regularly review scientific data to ensure medications remain as safe as possible.
Women should remember that every medication carries both benefits and potential risks. The best contraceptive choice depends on individual medical history, age, reproductive plans, and overall health.
Conclusion
The latest review by the European Medicines Agency highlights a small but measurable increase in the risk of meningioma associated with prolonged use of contraceptives containing desogestrel and etonogestrel.
However, the agency also emphasizes that the overall risk remains extremely low, with only about one additional case for every 67,300 women using these products.
For most women, hormonal contraceptives remain safe and highly effective. Those with a current or previous diagnosis of meningioma should discuss alternative contraceptive options with their healthcare provider.
Ultimately, informed decision-making, regular medical follow-up, and awareness of potential symptoms are the most effective ways to balance the benefits and risks of hormonal contraception.
Frequently Asked Questions (FAQ)
1. What is a meningioma?
A meningioma is usually a benign tumor that develops in the membranes surrounding the brain and spinal cord.
2. Do hormonal contraceptives cause brain tumors?
Current evidence suggests a slight increase in risk with prolonged use of certain progestin-containing contraceptives, but the overall likelihood remains very low.
3. Which contraceptives are included in the EMA warning?
The recommendation applies to contraceptives containing desogestrel and etonogestrel.
4. Should I stop taking my birth control immediately?
No. Women should consult their healthcare provider before making any changes to their contraceptive method.
5. Who should avoid these medications?
Women with a current or previous diagnosis of meningioma should avoid these specific hormonal contraceptives.
6. What symptoms should I watch for?
Persistent headaches, vision changes, hearing loss, balance problems, seizures, or memory difficulties should be evaluated by a healthcare professional.
7. Is the risk high?
No. The EMA estimates approximately one additional case per 67,300 users, making the overall risk extremely low.
8. Are all hormonal contraceptives affected?
No. The current recommendation specifically concerns products containing desogestrel and etonogestrel.
9. Can meningiomas be treated?
Yes. Most meningiomas are benign and can often be successfully managed with surgery, monitoring, or radiation therapy, depending on the case.
10. What is the safest approach?
Consult your healthcare provider to determine the contraceptive option that best matches your individual medical history and health needs.